冠状动脉疾病
外显子组测序
家族性高胆固醇血症
医学
他汀类
疾病
遗传学
内科学
生物
突变
基因
胆固醇
作者
Noura S. Abul‐Husn,Kandamurugu Manickam,Laney K. Jones,Eric A. Wright,Dustin N. Hartzel,Claudia Gonzaga‐Jauregui,Colm O’Dushlaine,Joseph B. Leader,H. Lester Kirchner,D’Andra M. Lindbuchler,Marci L Barr,Monica A. Giovanni,Marylyn D. Ritchie,John D. Overton,Jeffrey G. Reid,Raghu Metpally,Amr H. Wardeh,Ingrid B. Borecki,George D. Yancopoulos,Aris Baras
出处
期刊:Science
[American Association for the Advancement of Science (AAAS)]
日期:2016-12-22
卷期号:354 (6319)
被引量:419
标识
DOI:10.1126/science.aaf7000
摘要
Unleashing the power of precision medicine Precision medicine promises the ability to identify risks and treat patients on the basis of pathogenic genetic variation. Two studies combined exome sequencing results for over 50,000 people with their electronic health records. Dewey et al. found that ∼3.5% of individuals in their cohort had clinically actionable genetic variants. Many of these variants affected blood lipid levels that could influence cardiovascular health. Abul-Husn et al. extended these findings to investigate the genetics and treatment of familial hypercholesterolemia, a risk factor for cardiovascular disease, within their patient pool. Genetic screening helped identify at-risk patients who could benefit from increased treatment. Science , this issue p. 10.1126/science.aaf6814 , p. 10.1126/science.aaf7000
科研通智能强力驱动
Strongly Powered by AbleSci AI